不同剂量伏诺拉生治疗胃食管反流病:务实性交叉整群随机对照试验含患者偏好臂的研究方案
BACKGROUND: Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors.…
要点
- 伏诺拉生20 mg每日一次对30-40%的GERD患者不能达到治疗目标。
- 研究比较伏诺拉生20 mg早餐后、晚餐后及早晚各一次三种给药方案,疗程4周。
- 主要结局为4周治疗后全部患者的症状缓解率,次要结局包括EE愈合率等。
核心结论
- 该试验将探讨伏诺拉生不同给药方案在中国GERD患者中的有效性。
- 考虑患者偏好的随机化及交叉整群设计可能提高研究结论的稳健性和外推性。
研究设计与样本
- 务实性、开放标签、交叉整群随机对照试验,设患者偏好臂。
- 强制随机整群患者按交叉整群随机化分配至三种方案;患者偏好整群患者如有偏好可选择任一方案,否则随机分配。
- 三种治疗方案疗程均为4周:(1)伏诺拉生20 mg口服,早餐后;(2)伏诺拉生20 mg口服,晚餐后;(3)伏诺拉生20 mg口服,早餐后和晚餐后。
- 随访包括基线访视、4周电子日记、第4周访视和第6个月在线访视。
主要发现
- 主要结局为4周治疗后全部患者的症状缓解率。
- 次要结局包括EE患者的愈合率、症状严重程度、第4周随访时治疗依从性、症状复发及第6个月随访时自我意识就诊频率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors. It has only been approved for treating erosive esophagitis in China, but 30-40% of GERD patients cannot achieve the goal of treatment with vonoprazan 20 mg daily. This study aims to investigate whether vonoprazan could relieve the symptoms of Chinese patients with non-erosive reflux disease (NERD) and whether increased dosage or different times of dosing could increase the response rate of GERD. METHODS: This study is a pragmatic, open-label, crossover-cluster, randomized controlled trial with patient preference arms. Two thousand eight hundred eighty patients with GERD from 48 hospitals in China will be enrolled. These hospitals will be divided into a compulsory randomization cluster (24 hospitals) and a patient preference cluster (24 hospitals). Patients in the compulsory randomization cluster will be randomized to three regimens according to the crossover-cluster randomization. Patients in the patient preference cluster may choose to receive any regimen if they have a preference; otherwise, patients will be randomly assigned. The three treatment regimens will last 4 weeks, including (1) vonoprazan 20 mg p.o. after breakfast, (2) vonoprazan 20 mg p.o. after dinner, and (3) vonoprazan 20 mg p.o. after breakfast and after dinner. Patients will attend a baseline visit, a 4-week e-diary, a fourth-week visit, and a sixth-month visit online. The primary outcome is the symptom relief rate of all patients after 4-week therapy. Secondary outcomes include the healing rate of EE patients, the severity of symptoms, compliance with the therapy at the fourth-week follow-up visit, recurrent symptoms, and the frequency of self-conscious doctor visits at the sixth-month follow-up visit. DISCUSSION: This trial will explore the effectiveness of different regimens of vonoprazan that will be implemented with GERD patients in China. The randomization with patient preferences considered and the crossover-cluster component may improve the robustness and extrapolation of study conclusions. TRIAL REGISTRATION: https://www.chictr.org.cn ChiCTR2300069857. Registered on 28 March 2023. PROTOCOL VERSION: February 18, 2023, Version 2.
引用
- Wang D, Zhou D, Liu X, et al. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms. Trials. 2023. PMID: 38041136. doi:10.1186/s13063-023-07760-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。